Patents by Inventor Judith A. Fox

Judith A. Fox has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bispecific CD33 and CD3 Binding Proteins
    Publication number: 20210024654
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Application
    Filed: March 18, 2020
    Publication date: January 28, 2021
    Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
  • Bispecific CD33 and CD3 binding proteins
    Patent number: 10626190
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: April 21, 2020
    Assignee: Amphivena Therapeutics, Inc.
    Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
  • METHOD OF ADMINISTERING AN ANTIBODY
    Publication number: 20200002423
    Abstract: Disclosed is a method for treating a human having a disease associated with leukocyte infiltration of mucosal tissues, comprising administering to said human an effective amount of a human or humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for ?4?7 integrin. Preferably, no more than about 8 mg immunoglobulin or fragment per kg body weight are administered during a period of about one month.
    Type: Application
    Filed: November 2, 2018
    Publication date: January 2, 2020
    Inventors: Lee R. Brettman, Judith A. Fox, David Edward Allison
  • Bispecific CD33 and CD3 Binding Proteins
    Publication number: 20180291113
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Application
    Filed: October 27, 2017
    Publication date: October 11, 2018
    Inventors: Kristina ELLWANGER, Luke EVNIN, Judith A. FOX, Ivica FUCEK, Jeanmarie GUENOT, Stefan KNACKMUSS, Lori KUNKEL, Melvyn LITTLE, Vera MOLKENTHIN, Erich RAJKOVIC, Uwe REUSCH, Claudia WALL, Michael WEICHEL, Eugene ZHUKOVSKY
  • Bispecific CD33 and CD3 binding proteins
    Patent number: 9803029
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: October 31, 2017
    Assignee: AMPHIVENA THERAPEUTICS, INC.
    Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
  • METHODS OF USING SNS-595 FOR TREATMENT OF CANCER SUBJECTS WITH REDUCED BRCA2 ACTIVITY
    Publication number: 20170182015
    Abstract: Methods of using SNS-595 for treatment of a subject having cancer with BRCA2 mutation are described. In certain embodiments, the methods comprise administering a therapeutically effective amount of SNS-595 to a subject in need thereof.
    Type: Application
    Filed: August 10, 2016
    Publication date: June 29, 2017
    Inventors: Rachael E. Hawtin, Judith A. Fox
  • Bispecific CD33 and CD3 Binding Proteins
    Publication number: 20160194409
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Application
    Filed: November 10, 2015
    Publication date: July 7, 2016
    Inventors: Kristina ELLWANGER, Luke EVNIN, Judith A. FOX, Ivica FUCEK, Jeanmarie GUENOT, Stefan KNACKMUSS, Lori KUNKEL, Melvyn LITTLE, Vera MOLKENTHIN, Erich RAJKOVIC, Uwe REUSCH, Claudia WALL, Michael WEICHEL, Eugene ZHUKOVSKY
  • Bispecific CD33 and CD3 Binding Proteins
    Publication number: 20160002333
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Application
    Filed: March 9, 2015
    Publication date: January 7, 2016
    Inventors: Kristina ELLWANGER, Luke EVNIN, Judith A. FOX, Ivica FUCEK, Jeanmarie GUENOT, Stefan KNACKMUSS, Lori KUNKEL, Melvyn LITTLE, Vera MOLKENTHIN, Erich RAJKOVIC, Uwe REUSCH, Claudia WALL, Michael WEICHEL, Eugene ZHUKOVSKY
  • Bispecific CD33 and CD3 binding proteins
    Patent number: 9212225
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: December 15, 2015
    Assignee: AMPHIVENA THERAPEUTICS, INC.
    Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
  • METHODS OF USING SNS-595 FOR TREATMENT OF CANCER SUBJECTS WITH REDUCED BRCA2 ACTIVITY
    Publication number: 20150202189
    Abstract: Methods of using SNS-595 for treatment of a subject having cancer with BRCA2 mutation are described. In certain embodiments, the methods comprise administering a therapeutically effective amount of SNS-595 to a subject in need thereof.
    Type: Application
    Filed: September 3, 2014
    Publication date: July 23, 2015
    Inventors: Rachael E. HAWTIN, Judith A. Fox
  • METHOD OF ADMINISTERING AN ANTIBODY
    Publication number: 20140186345
    Abstract: Disclosed is a method for treating a human having a disease associated with leukocyte infiltration of mucosal tissues, comprising administering to said human an effective amount of a human or humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for ?4?7 integrin. Preferably, no more than about 8 mg immunoglobulin or fragment per kg body weight are administered during a period of about one month.
    Type: Application
    Filed: February 3, 2014
    Publication date: July 3, 2014
    Inventors: Lee R. Brettman, Judith A. Fox, David Edward Allison
  • CAB molecules
    Patent number: 8728470
    Abstract: The present invention relates to CAB molecules, ADEPT constructs directed against CEA, and their use in therapy.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: May 20, 2014
    Assignee: Danisco US Inc.
    Inventors: Judith A. Fox, Fiona A. Harding, Rashid M. Harunur, Volker Schellenberger
  • METHODS OF USING SNS-595 FOR TREATMENT OF CANCER SUBJECTS WITH REDUCED BRCA2 ACTIVITY
    Publication number: 20120148564
    Abstract: Methods of using SNS-595 for treatment of a subject having cancer with BRCA2 mutation are described. In certain embodiments, the methods comprise administering a therapeutically effective amount of SNS-595 to a subject in need thereof.
    Type: Application
    Filed: March 1, 2010
    Publication date: June 14, 2012
    Inventors: Rachael E. Hawtin, Judith A. Fox
  • Tab molecules
    Patent number: 8188240
    Abstract: The present invention relates to TAB molecules, ADEPT constructs directed against TAG-72, and their use in therapy.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: May 29, 2012
    Assignee: Danisco US Inc.
    Inventors: Judith A. Fox, M. Harunur Rashid, Martin Roberge, Volker Schellenberger
  • CAB MOLECULES
    Publication number: 20120107314
    Abstract: The present invention relates to CAB molecules, ADEPT constructs directed against CEA, and their use in therapy.
    Type: Application
    Filed: November 2, 2011
    Publication date: May 3, 2012
    Inventors: Judith A. Fox, Fiona A. Harding, Rashid M. Harunur, Volker Schellenberger
  • TAB MOLECULES
    Publication number: 20120094357
    Abstract: The present invention relates to TAB molecules, ADEPT constructs directed against TAG-72, and their use in therapy.
    Type: Application
    Filed: December 12, 2011
    Publication date: April 19, 2012
    Inventors: Judith A. Fox, M. Harunur Rashid, Martin Roberge, Volker Schellenberger
  • Method of Administering an Antibody
    Publication number: 20120034243
    Abstract: Disclosed is a method for treating a human having a disease associated with leukocyte infiltration of mucosal tissues, comprising administering to said human an effective amount of a human or humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for ?4?7 integrin. Preferably, no more than 8 mg immunoglobulin or fragment per kg body weight are administered during a period of about one month.
    Type: Application
    Filed: August 5, 2011
    Publication date: February 9, 2012
    Inventors: Lee R. Brettman, Judith A. Fox, David Edward Allison
  • TAB molecules
    Patent number: 8101728
    Abstract: The present invention relates to TAB molecules, ADEPT constructs directed against TAG-72, and their use in therapy.
    Type: Grant
    Filed: April 21, 2006
    Date of Patent: January 24, 2012
    Assignee: Danisco US Inc.
    Inventors: Judith A. Fox, M. Harunur Rashid, Martin Roberge, Volker Schellenberger
  • CAB molecules
    Patent number: 8088609
    Abstract: The present invention relates to CAB molecules, ADEPT constructs directed against CEA, and their use in therapy.
    Type: Grant
    Filed: April 12, 2005
    Date of Patent: January 3, 2012
    Assignee: Danisco US Inc.
    Inventors: Judith A. Fox, Fiona A. Harding, Rashid M. Harunur, Volker Schellenberger
  • Cab Molecules
    Publication number: 20110160440
    Abstract: The present invention relates to CAB molecules, ADEPT constructs directed against CEA, and their use in diagnosis and therapy.
    Type: Application
    Filed: December 10, 2004
    Publication date: June 30, 2011
    Applicant: GENENCOR INTERNATIONAL, INC.
    Inventors: Judith A. Fox, Fiona A. Harding, Volker Schellenberger